Vanda Pharmaceuticals Inc.
VQW-765
social anxiety disorder
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for VQW-765 in social anxiety disorder are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The Phase III study of VQW-765 in the treatment of adults with social anxiety disorder, with results expected by the end of 2026.”